Qurient and Synaffix partner to develop next-generation dual-payload ADCs

CAR-T Digest - August 2020

25 September 2025: Qurient and Synaffix partner to develop next-generation dual-payload ADCs

Qurient entered into a licensing agreement with Synaffix (a Lonza subsidiary) to develop next-generation dual-payload ADCs, integrating Qurient’s CDK7 inhibitor with Synaffix’s exatecan-based ADC technology
Qurient will lead research, development, commercialization, and production of its CDK7 inhibitor, while Synaffix and Lonza will provide ADC platform technologies (GlycoConnect, HydraSpace, SYNtecan) and manufacturing support
Dual-payload ADCs aim to enhance efficacy and reduce resistance by delivering two payloads with different mechanisms of action to targeted cancer cells, while minimizing toxicity
Collaboration addresses unmet medical needs in solid tumors, with potential to expand across diverse antibodies and multiple cancer targets